Phase 4 Haemophilia Trial, Recruiting NCT05936580 Sponsor: Octapharma Condition: Haemophilia
Back to Haemophilia

Phase 4 Haemophilia Trial, Recruiting

NCT05936580
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman or girl diagnosed with haemophilia A, with a clotting factor (FVIII) level below 40%, OR between 40–50% if you have a history of significant bleeding problems or have previously needed treatment for haemophilia A
  • You are at least 12 years old
  • You are scheduled to have a major surgery that will require clotting factor (FVIII) treatment — this includes planned or emergency surgery, or a planned caesarean section
  • You (or your parent/legal guardian if you are a minor) are able and willing to give written consent to take part in the trial

Who may not be able to join:

  • You have a blood clotting disorder other than haemophilia A
  • You have ever developed, or currently have, antibodies that block clotting factor treatment (called "inhibitors")
  • You have serious liver or kidney disease, based on specific blood test results (confirm with trial site)
  • You have a known allergy to the study drug (Nuwiq) or any of its ingredients, including sucrose, sodium chloride, or poloxamer 188
  • You are pregnant — unless you are taking part specifically because you have a planned caesarean section
  • You have already had a surgery as part of this study
  • You are currently taking part in another clinical trial that involves a treatment being tested
  • You have received an experimental/investigational medicine within the last 30 days before your screening appointment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Johannes Oldenburg, Experimental Haematology and Transfusion Medicine, University Clinic Bonn

Phone: +41795859042

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Octapharma
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 February 2027

Where this trial is recruiting

🇫🇮 Finland 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇷🇸 Serbia 🇪🇸 Spain 🇨🇭 Switzerland 🇬🇧 United Kingdom 🇺🇸 United States Uruguay

Primary endpoints

Overall haemostatic efficacy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov